AIX-EN-PROVENCE, FRANCE--(Marketwired - Apr 7, 2016) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), the highly innovative ultrasound imaging company, announced today its participation in two key conferences to demonstrate the clinical benefits of real-time ShearWave™ Elastography (SWE™) for the assessment and management of breast cancer.

SuperSonic Imagine's innovations are part of the Aixplorer® platform, the only ultrasound system available with ShearWave Elastography in real-time. SWE is a quick, non-invasive exam that provides practitioners a comprehensive and accurate tissue stiffness evaluation through a 2D color-coded map of elasticity in conjunction with a high quality grayscale ultrasound image. Tissue stiffness is used by physicians to better characterize lesions and therefore help identify potentially malignant or other diseased tissue.

The benefits of using the SuperSonic Imagine's ShearWave technology for the diagnosis of breast lesions have been demonstrated in more than 85 peer-reviewed publications, including a multinational study of over 1,600 patients. The results showed that SWE, combined with conventional ultrasound criteria from the BI-RADS®1 classification, allowed superior accuracy in the diagnosis of breast lesions and significantly reduced the number of false positive cases (improved specificity), as well as the number of false negative cases (improved sensitivity). By improving the accuracy of breast ultrasound, SuperSonic Imagine's SWE technology is especially helpful for women with dense breast tissue and helps to reduce the number of negative biopsies.

"Both of these conferences are important venues to demonstrate our real-time technology for breast cancer patient management and to discuss with practitioners its proven clinical benefits," said Jacques Souquet, SuperSonic Imagine's Chief Innovation Officer and Founder. "We remain committed to providing physicians and sonographers new and innovative tools for early detection of tissue stiffness in the breast and to significantly reduce the number of negative biopsies performed on women."

The Company will be exhibiting at booth #113 for the Society of Breast Imaging / American College of Radiology Breast Imaging Symposium April 7-9 Austin, Texas.

NCBC 2016 is taking place April 9-13, in Las Vegas, NV. The Company will be exhibiting at booth #125.

1. BI-RADS: Breast Imaging Reporting and Data System by the American College of Radiology Classification system used by radiologists, recommended for breast cancer screening, helping doctors to take appropriate action based on a classification system from ACR 1 to ACR 5 according to the probability of malignancy.

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to

Contact Information:

Contact information:

SuperSonic Imagine
Chief Executive Officer
Bernard Doorenbos

+33 6 15 66 64 68

SuperSonic Imagine
Marketing & Communication
Emmanuelle Vella

+33 4 86 79 03 27

Investor Relations - EU
Pierre Laurent
Florent Alba

+33 1 44 71 98 55

Pascale Communication
Media Relations - US
Amy Phillips

+1 412 327 9499